Overview

Thalidomide Maintenance Treatment in DLBCL

Status:
Recruiting

Trial end date:
2023-12-01

Target enrollment:

Participant gender:

Summary

This is a randomized, multi-center,phase III study to evaluate the ability of thalidomide maintenance therapy to prolong relapse-free survival in diffuse large B cell lymphoma(DLBCL).

Phase:

Phase 3

Details

Lead Sponsor:

Nanfang Hospital of Southern Medical University

Treatments:

Thalidomide